Oramed Pharmaceuticals Inc. plans a secondary listing in Tel Aviv “in the next few weeks” to take advantage of an increasing number of Israeli investors seeking new opportunities amid new measures to invigorate the stock market, CEO Nadav Kidron told Bloomberg.
